Full Press Release Details
Media
• August 8, 2023
IRWD Positive Sentiment
Ironwood Pharmaceuticals Reports Second Quarter 2023 Results; Raises Full Year 2023 LINZESS® U.S. Net Sales and Ironwood Revenue Guidance
Key Takeaway: Ironwood Pharmaceuticals announced its second quarter 2023 financial results, highlighting an increase in its full-year guidance for LINZESS U.S. net sales. The report indicates strong performance in the second quarter, contributing to a positive outlook for the company's revenue. This guidance adjustment reflects confidence in LINZESS's market performance.
Price reaction · baseline $11.35 (2023-08-07 close) · hit after-hours · clean, no other IRWD news in the window
day 0 close
-9.2%
day 1 · peak
-15.3%
day 3
-11.3%
Market Sentiment Analysis
POSITIVE FACTORS
- Ironwood Pharmaceuticals raised its full-year 2023 LINZESS U.S. net sales guidance.
- The company reported strong second quarter results.
- Positive outlook for Ironwood's revenue growth.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+57%
120-day peak, hindsight
Typical move
3.8%
average across 2 past catalysts
Lead asset
IW-3718
Phase 3 · Gastroesophageal Reflux Disease (GERD)
Frequently Asked Questions
What were Ironwood's Q2 2023 results?
Ironwood Pharmaceuticals reported strong financial results for Q2 2023.
What guidance did Ironwood raise?
Ironwood raised its full-year 2023 guidance for LINZESS U.S. net sales.
What is LINZESS?
LINZESS is a medication developed by Ironwood Pharmaceuticals.